NCT04150497 2025-09-09Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)Cellectis S.A.Phase 1/2 Recruiting52 enrolled